https://www.selleckchem.com/pr....oducts/actinomycin-d
7→270.2, 277.3→203.7, 220.3→242.0, and 454.1→313.0 for Naïve, BP, DMAb, and TPTD groups, respectively. Multivariate regression analysis revealed that significant predictors of LS BMD change at six months were prior treatment difference (r=-3.1, P=.0027) and TRACP-5b percentage change (r=-2.8, P=.0071) and PINP value at one month (r=3.2, P=.0021). Early effects of ROMO on the increase in LS BMD are significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. Early effec
Like
Comment
Share
